Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Recro Pharma Inc (REPH) USD0.01

Sell:$11.76 Buy:$11.77 Change: $0.25 (2.17%)
NASDAQ:0.30%
Market closed |  Prices as at close on 16 October 2019 | Switch to live prices |
Sell:$11.76
Buy:$11.77
Change: $0.25 (2.17%)
Market closed |  Prices as at close on 16 October 2019 | Switch to live prices |
Sell:$11.76
Buy:$11.77
Change: $0.25 (2.17%)
Market closed |  Prices as at close on 16 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.

Contact details

Address:
490 Lapp Rd
MALVERN
19355-1212
United States
Telephone:
+1 (484) 3952400
Website:
https://recropharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
REPH
ISIN:
US75629F1093
Market cap:
$258.37 million
Shares in issue:
22.43 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Wayne Weisman
    Independent Chairman of the Board
  • Geraldine Henwood
    President, Chief Executive Officer, Director
  • Ryan Lake
    Chief Financial Officer
  • Jyrki Mattila
    Executive Vice President - Business Development
  • Randall Mack
    Senior Vice President - Development, Secretary
  • Diane Myers
    Senior Vice President - Regulatory and Quality
  • Fred Graff
    Chief Commercial Officer
  • Stewart McCallum
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.